Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification)

Abstract

Purpose of reviewThe management of endometrial cancer has known many evolutions within the last decades. In this review, we aim to summarize recent evolutions (mainly toward less aggressive management) that have occurred in the management of endometrial cancer. Recent findingsEnhanced by molecular classification, the determination of lymph node status, in young women, in case of cervical invasion, the treatment is evolving toward a less aggressive strategy.

OS and DFS are affected by different diagnostic methods and hysterectomy procedures in endometrial cancer patients: A single‐center retrospective study

“…RH with bilateral salpingo‐oophorectomy (BSO) is recommended for patients with stage II EC based on guidelines before 2014 26 . However, since 2015, some studies have found that RH does not improve the prognosis of patients with stage II EC 27,28 . Nevertheless, the latest NCCN guidelines for uterine neoplasms in 2023 still recommend total hysterectomy or RH and BSO and surgical staging for stage II EC 29 .…”

“… 26 However, since 2015, some studies have found that RH does not improve the prognosis of patients with stage II EC. 27 , 28 Nevertheless, the latest NCCN guidelines for uterine neoplasms in 2023 still recommend total hysterectomy or RH and BSO and surgical staging for stage II EC. 29 The hypothesis was that RH could remove histologic parametrial involvement (PMI) in patients with cervical involvement because the incidence of PMI among FIGO stage II patients is 11.5%–14.1%.…”